AI-Generated Medical Consent Form Market Outlook

According to our latest research, the global AI-Generated Medical Consent Form market size reached USD 1.14 billion in 2024, reflecting a robust adoption of AI technologies across healthcare documentation. The market is poised to grow at a CAGR of 21.7% from 2025 to 2033, with the forecasted market size expected to reach USD 8.43 billion by 2033. This remarkable growth is primarily driven by the increasing demand for digital transformation in healthcare, the need for enhanced patient data security, and the rising complexity of regulatory compliance worldwide.

One of the most significant growth factors in the AI-Generated Medical Consent Form market is the urgent need for efficiency and accuracy in healthcare documentation. Traditional consent processes are often paper-based, time-consuming, and susceptible to human error, which can lead to legal complications and patient dissatisfaction. AI-generated solutions automate the creation, customization, and management of consent forms, ensuring compliance with evolving medical regulations and standards. These platforms can rapidly adapt to new legal requirements, translate forms into multiple languages, and personalize content based on patient demographics or specific clinical scenarios, thereby improving both workflow efficiency and patient comprehension. The growing emphasis on patient-centric care, coupled with the necessity for error-free documentation, has significantly accelerated the adoption of AI-driven consent solutions globally.

Another key driver for market expansion is the surge in telemedicine and remote healthcare services, especially post-pandemic. As healthcare providers increasingly deliver services beyond traditional clinical settings, the demand for secure, accessible, and legally compliant electronic consent solutions has surged. AI-generated consent forms can be integrated seamlessly into telemedicine platforms, enabling patients to review, understand, and sign documents remotely. This not only facilitates broader access to healthcare but also ensures that providers maintain robust legal and ethical standards. Moreover, AI-powered analytics embedded within these systems can track patient engagement and comprehension, offering insights that help providers tailor communication strategies and further reduce risks associated with consent misunderstandings.

The market is also benefiting from heightened regulatory scrutiny and the proliferation of data privacy laws such as GDPR, HIPAA, and similar frameworks in Asia Pacific and Latin America. These regulations require healthcare providers to ensure explicit, informed consent for the collection and use of patient data. AI-generated consent form solutions are uniquely positioned to address these requirements by automating compliance checks, maintaining detailed audit trails, and updating consent language in real time as regulations evolve. As healthcare organizations face increasing penalties for non-compliance, investment in AI-driven consent technologies has become a strategic imperative. This trend is expected to intensify as global regulators introduce stricter standards for patient data protection and informed consent.

From a regional perspective, North America currently leads the AI-Generated Medical Consent Form market, accounting for the largest share in 2024, driven by early adoption of digital health technologies, strong regulatory frameworks, and a high concentration of leading market players. Europe follows closely, with growth propelled by stringent data protection laws and a rapidly aging population that demands more efficient healthcare processes. The Asia Pacific region is emerging as the fastest-growing market, supported by expanding healthcare infrastructure, rising investments in health IT, and increasing awareness of digital consent solutions among providers and patients. Latin America and the Middle East & Africa are also witnessing gradual adoption, primarily fueled by government initiatives to digitize healthcare and improve patient safety standards.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

The deidentified data in the “COVID-19 Case Surveillance Public Use Data” include demographic characteristics, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and presence of any underlying medical conditions and risk behaviors. All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 Case Reports

COVID-19 case reports have been routinely submitted using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for laboratory-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.
• Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question “Was the individual hospitalized?” where the possible answer choices include “Yes,” “No,” or “Unknown,” the blank value is recoded to Missing because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race and ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<5) records and indirect identifiers (e.g., date of first positive specimen). Suppression includes rare combinations of demographic characteristics (sex, age group, race/ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

For questions, please contact Ask SRRG (eocevent394@cdc.gov).

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These

The Dempgraphics file contains: Sample ID, participant age, sex and label - HC (Healthy Control) or PwPD (Patient with Parkinson's Disease). The Sample ID is a key that links to the voice recording files PD_AH.zip and HC_AH.zip.Voice recordings are in .wav format and represent a prolonged enunciation of the vowel /a/. These recordings were made using participant's telephones.

Emergency medical services (EMS) workforce demographics in the United States do not reflect the diversity of the population served. Despite some efforts by professional organizations to create a more representative workforce, little has changed in the last decade. This scoping review aims to summarize existing literature on the demographic composition, recruitment, retention, and workplace experience of underrepresented groups within EMS. Peer-reviewed studies were obtained from a search of PubMed, CINAHL, Web of Science, ProQuest Thesis and Dissertations, and non-peer-reviewed (“gray”) literature from 1960 to present. Abstracts and included full-text articles were screened by two independent reviewers trained on inclusion/exclusion criteria. Studies were included if they pertained to the demographics, training, hiring, retention, promotion, compensation, or workplace experience of underrepresented groups in United States EMS by race, ethnicity, sexual orientation, or gender. Studies of non-EMS fire department activities were excluded. Disputes were resolved by two authors. A single reviewer screened the gray literature. Data extraction was performed using a standardized electronic form. Results were summarized qualitatively. We identified 87 relevant full-text articles from the peer-reviewed literature and 250 items of gray literature. Primary themes emerging from peer-reviewed literature included workplace experience (n = 48), demographics (n = 12), workforce entry and exit (n = 8), education and testing (n = 7), compensation and benefits (n = 5), and leadership, mentorship, and promotion (n = 4). Most articles focused on sex/gender comparisons (65/87, 75%), followed by race/ethnicity comparisons (42/87, 48%). Few articles examined sexual orientation (3/87, 3%). One study focused on telecommunicators and three included EMS physicians. Most studies (n = 60, 69%) were published in the last decade. In the gray literature, media articles (216/250, 86%) demonstrated significant industry discourse surrounding these primary themes. Existing EMS workforce research demonstrates continued underrepresentation of women and nonwhite personnel. Additionally, these studies raise concerns for pervasive negative workplace experiences including sexual harassment and factors that negatively affect recruitment and retention, including bias in candidate testing, a gender pay gap, and unequal promotion opportunities. Additional research is needed to elucidate recruitment and retention program efficacy, the demographic composition of EMS leadership, and the prevalence of racial harassment and discrimination in this workforce.

Demographic reports on TSP participant behavior and investment manager diversity are reported annually to Congress and available to the public via FRTIB’s Open Data Plan. Reports are in PDF format with included data tables.

Bismuth Subsalicylate Market Outlook

The global Bismuth Subsalicylate market size stood at approximately USD 700 million in 2023 and is expected to reach around USD 1.1 billion by 2032, growing at a CAGR of 5.3% during the forecast period. This growth is attributed to the increasing prevalence of gastrointestinal disorders and the rising demand for over-the-counter medications. The growing awareness about the benefits of Bismuth Subsalicylate in treating various digestive ailments is also a significant factor propelling market growth.

One of the primary drivers of the Bismuth Subsalicylate market is the increasing incidence of gastrointestinal disorders worldwide. Modern lifestyles, characterized by poor dietary habits and increased stress levels, have contributed significantly to the rise in gastrointestinal issues such as diarrhea, nausea, heartburn, and indigestion. Additionally, the aging population, which is more prone to these disorders, further fuels the demand for effective treatments like Bismuth Subsalicylate, thus driving market growth.

Another significant growth factor for the Bismuth Subsalicylate market is the expanding availability of over-the-counter (OTC) medications. With the increasing willingness of consumers to self-medicate for minor ailments, the demand for readily accessible and effective treatments has surged. Bismuth Subsalicylate, known for its efficacy and safety, is a popular choice among consumers. The ease of purchasing OTC medications from pharmacies, supermarkets, and online stores also contributes to the market's expansion.

The ongoing advancements in pharmaceutical technology also play a crucial role in the market's growth. Innovations in drug formulation and delivery systems have enhanced the efficacy and patient compliance of Bismuth Subsalicylate products. The development of new forms such as chewable tablets and improved liquid formulations has made the medication more convenient and appealing to various patient demographics, thus boosting the market further.

From a regional perspective, North America holds a significant share of the Bismuth Subsalicylate market due to the high prevalence of gastrointestinal disorders and the widespread availability of OTC medications. The well-established healthcare infrastructure and high consumer awareness in this region also contribute to market growth. In contrast, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period. The increasing population, rising disposable incomes, and improving healthcare access in this region are expected to drive the demand for Bismuth Subsalicylate products significantly.

Form Analysis

The Bismuth Subsalicylate market is segmented by form, which includes tablets, liquid, and chewable forms. The tablet form holds a substantial share of the market due to its convenience and ease of use. Tablets are preferred by a broad demographic, including older adults and travelers, due to their portability, precise dosing, and longer shelf life. The well-established distribution channels and consumer familiarity with tablet-based medications also contribute to their dominance in the market.

The liquid form of Bismuth Subsalicylate is also a significant segment, particularly favored for its rapid action and ease of ingestion, especially among children and the elderly who may have difficulty swallowing tablets. Liquid formulations are essential in acute settings where immediate relief from gastrointestinal discomfort is required. The advancements in liquid drug formulations, ensuring better taste and enhanced stability, have further boosted the popularity of this form.

Chewable Bismuth Subsalicylate has emerged as a popular choice in recent years, particularly among younger populations and individuals looking for a more palatable alternative to traditional tablets. Chewable forms offer the convenience of not requiring water for ingestion, making them ideal for on-the-go use. The increasing innovation in flavor and formulation has made chewable options more appealing, contributing to their growing market share.

Each form of Bismuth Subsalicylate serves distinct consumer needs and preferences. While tablets remain a staple due to their reliability and convenience, the liquid form is indispensable for specific patient groups requiring faster relief and easier administration. The chewable form is gaining traction for its user-friendly attributes and improved patient compliance. The market dynamics for each form are shaped by consumer preferen

Gleevec Market size was valued at USD 344 Million in 2023 and is projected to reach USD 644.7 Million by 2031, growing at a CAGR of 8.29% during the forecast period 2024-2031.

Global Gleevec Market Drivers The market drivers for the Gleevec Market can be influenced by various factors. These may include:

Increasing Cancer Incidence: The rising incidence of cancer, particularly chronic myeloid leukemia (CML), is a key driver for the Gleevec market. As more individuals are diagnosed with cancer, the demand for effective treatment options, such as Gleevec, continues to grow. According to global cancer statistics, the prevalence of CML and other cancers has been on the rise due to factors like aging populations and lifestyle choices. This growing patient population increases the need for targeted therapies. Consequently, pharmaceutical companies are focusing on Gleevec’s market expansion, making it a critical component of cancer treatment regimens worldwide, leading to sustained revenue streams for manufacturers. Patent Expiration and Generic Competition: The expiration of Gleevec’s patent created a significant shift in the market dynamics. Once the patent lapsed, generic versions of imatinib flooded the market, resulting in decreased prices and accessibility for patients. This influx of generics intensified competition, causing brand-name Gleevec to lose market share. However, while this presents challenges, it also drives market efficiency, providing patients with more affordable treatment options. Generics have diversified the market while ensuring that more individuals receive life-saving therapies. As healthcare systems adapt, the competition encourages continuous innovation within the pharmaceutical industry to capture unmet medical needs in cancer therapies.

Global Gleevec Market Restraints Several factors can act as restraints or challenges for the Gleevec Market. These may include:

High Cost of Medication: The Gleevec market faces significant restraint due to the high cost of the medication. With a price tag often exceeding several thousand dollars monthly, affordability becomes a barrier for many patients, particularly in low- and middle-income countries. High out-of-pocket expenses may deter patients from initiating or continuing treatment, leading to reduced market penetration. As healthcare systems around the world grapple with rising pharmaceutical costs, the pressure to provide affordable treatment options intensifies. Furthermore, insurance coverage discrepancies create disparities in access, hindering Gleevec’s market growth despite its proven efficacy against certain cancers. Generic Competition: The entry of generic alternatives poses a substantial restraint to the Gleevec market. Once the patent for Gleevec expired, several pharmaceutical companies began to produce generic versions, offering lower-priced alternatives that challenge Novartis’ original product. This increased competition compresses profit margins and may shift consumer choice towards more affordable options. Additionally, healthcare providers may favor generics under cost-saving initiatives, further limiting Gleevec’s market share. As regulatory bodies encourage the use of generics to improve access to life-saving medications, Gleevec faces ongoing pressure from this influx of competitive pricing, impacting future sales.

Prospective registry and biorepository of consecutive patients who present to emergency departments in the Detroit Medical Center with (1) an established history of hypertension (HTN) or (2) elevated blood pressure with no history of HTN. Patients are surveyed using validated Survey instruments including the SF-12 Health Survey, Patient Activation Measure short form (PAM-13), Berlin Obstructive Sleep Apnea Scale, Social Support Questionnaire short form (SSQ-6), Perceived Stress Scale (PSS-14), MacArthur Scale of Subjective Social Status, Six-Item Cognitive Impairment Test (6-CIT), and Brief Coping Orientation to Problems Experienced (Brief COPE). Biological specimens are obtained from consenting individuals. Other collected data include patient demographics, vital signs, physical examination, basic medical history, medications, electrocardiography, x-ray, and lab results.

The data is prepared using AmeriCorps members who began service on any day in fiscal year (FY) 2017. The members may have served 1 to 365 days during their term. Members who are in never served, disqualified, pre-service, or deferred statuses were excluded from this analysis. AmeriCorps VISTA and AmeriCorps NCCC race and ethnicity data come from the member application to serve. The code to extract the data between the two programs is the same. The ASN race and ethnicity data comes from the enrollment form. The enrollment form may exist multiple times if the member enrolled in more than one term. It is not uncommon for each enrollment form to have conflicting information about the member’s race and ethnicity. The member may have enrollment form data for terms served outside of the timeframe of the dataset. For example, if we are reporting on members who began service in FY17, then a member who also served in FY16 may have race and ethnicity information in the FY16 enrollment form and no race or ethnicity information or conflicting information in the FY17 enrollment form. In the case of conflicting information, this analysis assumes each instance of race designation is correct. If a member reports themselves as “Asian or Asian American” in one enrollment form and “White” in another enrollment form, then the analysis categorizes this person as someone who identifies with multiple race selections vs. one or the other. In the case of ethnicity, if a member indicates that they are not Hispanic or Latino/a in one form, but that they are in another, this analysis assumes the affirmative—and they will be categorized as Hispanic or Latino/a. Lastly, the totals include the total results from the query plus the difference between the query and the raw count of members who started service in that fiscal year. The members who did not have a record in the invite table and enrollment table were added to the non-response category. Senior Corps Figures come from the Annual Progress Report Supplement as of April 11, 2018. Percentages are calculated from totals of the subcategories, excluding the non-response categories.

Riluzole Tablet Market Outlook

The global Riluzole tablet market size in 2023 is estimated to be approximately USD 0.5 billion and is projected to reach USD 0.8 billion by 2032, growing at a CAGR of 5.5% during the forecast period. The growth of this market is primarily driven by the increasing prevalence of Amyotrophic Lateral Sclerosis (ALS), an incurable progressive neurodegenerative disease, which has heightened the demand for Riluzole as one of the few approved treatments available. This, coupled with advancements in pharmaceutical formulations and enhanced drug delivery mechanisms, has further expanded the market potential, making Riluzole a cornerstone in ALS management protocols across the globe.

The rising incidence of ALS globally is one of the primary factors contributing to the growth of the Riluzole tablet market. Recent epidemiological studies indicate that ALS affects approximately 5 to 10 per 100,000 individuals worldwide, and these numbers are expected to rise with an aging population, particularly in developed economies. This increase is further exacerbated by heightened awareness and improved diagnostic capabilities, facilitating timely interventions that include the usage of Riluzole. Moreover, the continuous efforts by pharmaceutical companies to improve the therapeutic efficacy and reduce the side effects of Riluzole tablets have made them more appealing to healthcare professionals, thereby boosting market growth.

Additionally, the market growth is catalyzed by strategic collaborations and partnerships between pharmaceutical companies and research institutions aimed at enhancing the understanding of ALS pathophysiology and developing novel treatment regimens. These partnerships are crucial for fostering innovation and ensuring that Riluzole formulations remain relevant in the ever-evolving pharmaceutical landscape. Furthermore, governmental and non-governmental organizations are increasingly investing in the research and development of ALS treatments, thereby providing a robust framework that supports the growth of the Riluzole market. This comprehensive approach not only aids in drug innovation but also ensures that these treatments are accessible to a broader patient demographic.

The introduction of generic versions of Riluzole tablets has also played a significant role in expanding market reach, particularly in cost-sensitive regions. The availability of affordable treatment options ensures that a larger segment of the population can access this critical medication, thus driving market growth. In addition, the expansion of distribution channels, such as online pharmacies, has increased the accessibility of Riluzole tablets, making them available to patients who might have previously faced geographical or logistical barriers. This ease of access is particularly beneficial in rural or underserved areas where traditional pharmacy infrastructure may be lacking.

Regionally, North America dominates the Riluzole tablet market, accounting for the largest share due to high healthcare expenditure, advanced healthcare infrastructure, and a strong focus on research and development. The Asia Pacific region is expected to witness the fastest growth over the forecast period, driven by increasing healthcare awareness, rising disposable incomes, and improving healthcare infrastructure. Europe also holds a significant share of the market, with countries like Germany, France, and the UK leading due to their robust healthcare systems and high prevalence of ALS. Meanwhile, regions like Latin America and the Middle East & Africa are gradually emerging as potential markets due to rising awareness and improving healthcare services.

Dosage Form Analysis

The Riluzole tablet market is segmented by dosage form, including 50 mg, 100 mg, and others, with each dosage catering to specific therapeutic needs and patient demographics. The 50 mg dosage form holds a significant share of the market, primarily used as the standard dose for ALS treatment. Its widespread acceptance among healthcare providers is attributed to its balance between efficacy and safety, making it a preferred choice for long-term management of ALS symptoms. The established dosing regimen ensures patient adherence while minimizing the risk of adverse effects, which is crucial for maintaining the patient's quality of life over the course of the disease.

The 100 mg dosage form, though less commonly prescribed, serves critical roles in specific clinical scenarios where higher doses are deemed necessary by healthcare providers. This dosage is particularly relevant in cases where the patient exhibit

Key Table Information.Table Title.Nonemployer Statistics by Demographics series (NES-D): Legal Form of Organization Statistics for Nonemployer Firms by Industry, Sex, Ethnicity, Race, and Veteran Status for the U.S., States, Metro Areas, and Counties: 2022.Table ID.ABSNESD2022.AB2200NESD03.Survey/Program.Economic Surveys.Year.2022.Dataset.ECNSVY Nonemployer Statistics by Demographics Company Summary.Source.U.S. Census Bureau, 2022 Economic Surveys, Nonemployer Statistics by Demographics.Release Date.2025-05-08.Release Schedule.The Nonemployer Statistics by Demographics (NES-D) is released yearly, beginning in 2017..Sponsor.National Center for Science and Engineering Statistics, U.S. National Science Foundation.Table Universe.Includes U.S. firms with no paid employment or payroll, annual receipts of $1,000 or more ($1 or more in the construction industries) and filing Internal Revenue Service (IRS) tax forms for sole proprietorships (Form 1040, Schedule C), partnerships (Form 1065), or corporations (the Form 1120 series).Data are also obtained from administrative records, the 2022 Economic Census, and other economic surveys..Methodology.Data Items and Other Identifying Records.Number of nonemployer firmsSales, value of shipments, or revenue of nonemployer firms ($1,000)These data are aggregated by sex, ethnicity, race, and veteran status when classifiable.The data are also shown by the following legal form of organization (LFO) categories: S-Corporations C-Corporations Individual proprietorships Partnerships Definitions can be found by clicking on the column header in the table or by accessing the Economic Census Glossary..Unit(s) of Observation.The reporting units for the NES-D and the ABS are companies or firms rather than establishments. A company or firm is comprised of one or more in-scope establishments that operate under the ownership or control of a single organization..Geography Coverage.The 2022 data are shown for the total of all sectors (00) and the 2-digit NAICS code levels for:United StatesStates and the District of ColumbiaIn addition, the total of all sectors (00) NAICS is shown for:Metropolitan Statistical AreasMicropolitan Statistical AreasCountiesFor information about geographies, see Geographies..Industry Coverage.The data are shown for the total of all sectors ("00"), and at the 2-digit NAICS code levels depending on geography. Sector "00" is not an official NAICS sector but is rather a way to indicate a total for multiple sectors. Note: Other programs outside of ABS may use sector 00 to indicate when multiple NAICS sectors are being displayed within the same table and/or dataset.The following are excluded from the total of all sectors:Crop and Animal Production (NAICS 111 and 112)Rail Transportation (NAICS 482)Postal Service (NAICS 491)Monetary Authorities-Central Bank (NAICS 521)Funds, Trusts, and Other Financial Vehicles (NAICS 525)Office of Notaries (NAICS 541120)Religious, Grantmaking, Civic, Professional, and Similar Organizations (NAICS 813)Private Households (NAICS 814)Public Administration (NAICS 92)For information about NAICS, see North American Industry Classification System..Sampling.NES-D nonemployer data are not conducted through sampling. Nonemployer Statistics (NES) data originate from statistical information obtained through business income tax records that the Internal Revenue Service (IRS) provides to the Census Bureau. The NES-D adds demographic characteristics to the NES data and produces the total firm counts and the total receipts by those demographic characteristics. The NES-D utilizes various administrative records (AR) and the Census Bureau data sources that include the Business Register (BR), Internal Revenue Service (IRS) tax Form 1040 data, tax Schedule K-1 data, Decennial Census and American Community Survey (ACS) data, Social Security Administration's database (Numident), and AR from the Department of Veterans Affairs (VA).For more information, see Nonemployer Statistics by Demographics Methodology..Confidentiality.The Census Bureau has reviewed this data product to ensure appropriate access, use, and disclosure avoidance protection of the confidential source data (Project No. P-7504866, Disclosure Review Board (DRB) approval number: CBDRB-FY25-0195).This dataset contains both nonemployer and employer data.For the nonemployer data, the NES-D uses noise infusion as the primary method of disclosure avoidance for receipts, and In certain circumstances, some individual cells may be suppressed for additional disclosure avoidance. More information on nonemployer firm disclosure avoidance is available in the Nonemployer Statistics by Demographics Methodology.For the employer data, data rows with high relative standard errors (RSE) are not presented. Additionally, firm counts are suppressed when other select statistics in the same row are suppressed. More information on employer firm disclosure avoidance is available in the Annual Business Survey Methodology..Te...

Patients’ demographics and health status.

Arbidol Market Outlook

The global Arbidol market size was valued at approximately USD 1.4 billion in 2023 and is projected to reach around USD 2.6 billion by 2032, growing at a compound annual growth rate (CAGR) of 7%. The market growth is driven by the increasing prevalence of influenza and respiratory infections globally. Additionally, growing awareness about the benefits of antiviral medications is significantly contributing to market expansion.

The primary growth factor for the Arbidol market is the rising incidence of influenza and other respiratory infections worldwide. Seasonal flu outbreaks, pandemics, and the emergence of new viral strains have heightened the need for effective antiviral treatments. Arbidol, being known for its efficacy in treating these conditions, has consequently seen an increase in demand. Moreover, the COVID-19 pandemic has underscored the importance of antiviral medications, bringing renewed attention and investment into this sector.

Another significant factor driving market growth is the continuous advancement in pharmaceutical research and development. Companies are investing in innovative formulations and drug delivery mechanisms to enhance the efficacy and patient compliance of Arbidol. This ongoing research is expected to yield new and improved versions of the drug, catering to diverse patient needs and expanding the market base. Furthermore, government initiatives and funding in healthcare infrastructure improvements are also bolstering the market’s growth trajectory.

The shift in consumer behavior towards preventive healthcare measures has also played a crucial role. With a growing emphasis on maintaining health and preventing diseases through medication, there is a higher adoption rate of antiviral drugs like Arbidol. Moreover, increased healthcare expenditure and improved access to healthcare services in emerging economies are providing a substantial boost to the market. As more people gain access to healthcare services, the demand for effective antiviral medications is set to rise.

Regionally, the Asia Pacific dominates the Arbidol market due to the high prevalence of respiratory infections and a large patient pool. Countries like China and India are significant contributors to the market owing to their substantial population base and rising healthcare awareness. North America and Europe follow suit with significant market shares, driven by advanced healthcare systems and high healthcare spending. Latin America and the Middle East & Africa regions are also showing promising growth potential, supported by improving healthcare infrastructure and rising healthcare investments.

Dosage Form Analysis

The Arbidol market is segmented into various dosage forms, including tablets, capsules, and syrup. Among these, tablets hold the largest market share due to their ease of administration, longer shelf life, and higher patient compliance. Tablets are preferred by both healthcare providers and patients, especially for chronic conditions requiring long-term medication. The stability and convenience offered by tablets make them a widely accepted form of medication.

Capsules are also gaining traction in the Arbidol market. They offer advantages such as better bioavailability and faster absorption, which are critical for antiviral medications where quick action is often required. The encapsulation also helps in masking the taste of the drug, enhancing patient compliance. Research and development in capsule technology are further expected to improve the efficacy and appeal of this dosage form, making it a significant segment in the market.

Syrup formulations are particularly important for pediatric and geriatric patients who may have difficulty swallowing tablets or capsules. The syrup form allows for easier dose adjustment and can be more palatable, making it suitable for children. As the focus on pediatric healthcare grows, the market for Arbidol syrup is expected to expand. Innovations in flavoring and preservation are also likely to boost the demand for syrup formulations.

The continuous demand for each dosage form is driven by specific patient demographics and their unique needs. For instance, adults and older patients often prefer tablets and capsules for convenience, while children and elderly individuals with swallowing difficulties may benefit more from syrup formulations. The pharmaceutical industry’s focus on meeting these diverse needs ensures a balanced growth for all dosage forms in the Arbidol market.

The Nonemployer Statistics by Demographics (NES-D): Characteristics of Business Owners estimates provide information on selected economic and demographic characteristics of business owners tabulated by sex, ethnicity, race, and veteran status of an owner. Included in the universe are nonemployer businesses with no paid employment or payroll, annual receipts of $1,000 or more ($1 or more in the construction industries), and filing IRS tax forms for sole proprietorships (Form 1040, Schedule C), partnerships (Form 1065), or corporations (the Form 1120 series).

Demographics of the 176 house staff with a MOLST knowledge score >16 by self-reported comfort discussing the choices on a MOLST form with patients.

The dataset contains pediatric CIN admissions due to diarrhoea and dehydration from 2013 to 2019 and were used to access the trends in hospitalization following the introduction of rotavirus vaccine. Standardized pediatric admission record (PAR) forms were used to capture the patient’s demographic and clinical details during admission. Discharge summary forms were also used to capture all the patient’s discharge details including diagnosis and whether they are alive or dead. It contains 12 variables including patients’ demographics and clinical signs used to identify diarrhoea and dehydration cases: 1. Time - time 2. age_months - age in months 3. hosp_id - Hospital identifier 4. child_sex - gender 5. pulse - pulse rate 6. cap_refill_cat - time until capillary refill 7. skin_temp - skin tempereture 8. sunk_eyes - sunken eyes 9. skin_pinch- time taken for skin to return to normal after pinching 10. avpu- alertness 11. can_drink - ability to drink 12. month.year - date in months/year

Introduction: Despite the rising availability and use of medical marijuana (MM) in the U.S., little is known about the demographics, clinical characteristics, or quality of life of MM patients. This study describes the demographic characteristics and health-related quality of life (HRQoL) of MM patients who are initiating treatment in Pennsylvania. Methods: Two hundred adults naive to MM and referred for any of the 23 state-approved qualifying conditions were recruited at three MM dispensaries in Pennsylvania between September 2020 and March 2021. All participants consented to the study, completed semi-structured interviews that included demographic questionnaires, the Short Form-36 (SF-36), and Generalized Anxiety Disorder-7 (GAD-7), provided height and weight measurements, and allowed access to their dispensary medical records. Results: Participants had a mean age of 48.5 ±15.6 years, predominantly identified as female (67.5 %), and were most commonly referred for chronic pain (63.5%...

Dapsone Market Outlook

The global dapsone market size was valued at approximately USD 1.2 billion in 2023, and it is projected to reach USD 2.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.2% during the forecast period. The growth of this market is driven by the increasing prevalence of dermatological conditions and infectious diseases, alongside ongoing research and development in novel therapeutic applications. With a constant rise in skin-related issues such as acne vulgaris and leprosy, the demand for effective treatments like dapsone is projected to surge, substantially contributing to market growth. Furthermore, the expansion of distribution channels and the growing availability of generic drugs are expected to bolster market dynamics over the next decade.

One of the primary growth factors for the dapsone market is the rising incidence of dermatological disorders worldwide. The increasing number of cases of acne, dermatitis, and leprosy has propelled the demand for effective treatment options, positioning dapsone as a critical therapeutic agent. Dermatology, as a segment, remains a significant driver, owing to the compound's efficacy in treating a range of skin conditions. Research advancements in dermatological applications are further expected to enhance the market's growth trajectory, with ongoing studies exploring new formulations and modes of application. The increasing awareness of skin health, coupled with the growing inclination toward maintaining a healthy dermatological profile, is anticipated to spur the demand for dapsone-based products significantly.

Infectious diseases represent another vital growth driver for the dapsone market. The resurgence of infectious conditions such as leprosy and malaria in certain regions has underscored the need for effective antimicrobial treatments. Dapsone's role as an essential component in multi-drug therapy for leprosy highlights its importance in infectious disease management. As global health initiatives continue to focus on eradicating neglected tropical diseases, the demand for dapsone is expected to experience a favorable uptrend. Additionally, the ongoing research into dapsone's potential in combating emerging infectious diseases offers promising prospects for market expansion. The compound's broad-spectrum antimicrobial properties make it a valuable asset in addressing both existing and emerging health threats.

Furthermore, advancements in drug formulation technology are creating new growth avenues for the dapsone market. Innovations in dapsone delivery systems, such as gels and creams, have enhanced its therapeutic effectiveness and patient compliance, fueling market growth. These novel formulations are designed to improve drug absorption and reduce systemic side effects, thereby increasing the medication's acceptability among both healthcare providers and patients. The integration of cutting-edge technologies in drug development processes is anticipated to drive the market forward by offering more efficient and patient-friendly dapsone products. As pharmaceutical companies continue to invest in research and development, the pipeline for new dapsone formulations is expected to expand, providing new opportunities for market stakeholders.

Product Form Analysis

In the dapsone market, product form plays a critical role in determining its application and accessibility across diverse patient demographics. The tablet form of dapsone remains the most commonly used, primarily due to its convenience and widespread availability. Tablets are favored in both hospital and retail pharmacy settings, offering a reliable means of administration for chronic conditions like leprosy and dermatitis herpetiformis. The stability and shelf-life offered by tablet forms contribute significantly to their dominance in the market. The ease of dosage accuracy with tablets also enhances their appeal, ensuring patients receive the correct therapeutic quantities. Despite the dominance of tablets, technological advancements in pharmaceutical formulations are paving the way for more innovative product forms, including gels and creams.

The gel form of dapsone has witnessed significant growth, driven by its increased adoption in dermatological applications. Gels offer the advantage of targeted delivery, which is particularly beneficial in treating localized skin conditions such as acne. The rise in popularity of topical treatments has propelled the demand for gel formulations, as they generally lead to fewer systemic side effects compared to oral medications. Patients find gels preferable due to their ease of application and ra